MIDLAND, MI and SAINT JOHNS, MI / ACCESSWIRE / November 14, 2024 / Michigan Psychological Care is excited to announce the addition of psychiatry services, also known as medication management, to its comprehensive suite of mental health care options. Accepting all insurances and with no waitlist, individuals can now receive the medication support they need without delay from pediatrics to geriatrics.
“Our goal has always been to make mental health care accessible and timely for all,” said Lara Hakamaki, Director of Corporate Development at Michigan Psychological Care. “With the introduction of psychiatric nurse practitioners, we are expanding our commitment to offer the best possible care, whether it’s through therapy, psychological evaluations, or medication management.”
This new service offers patients personalized medication treatment for conditions such as anxiety, depression, ADHD, and more. With licensed psychiatric nurse practitioners on staff and convenient locations across Michigan, the clinic is ready to meet the growing demand for mental health support.
Michigan Psychological Care has been serving communities across Michigan with a holistic approach to mental health, offering individual therapy, group therapy, family and couples counseling, psychological evaluations, and now, psychiatry services.
###
About Michigan Psychological Care
Michigan Psychological Care is dedicated to providing compassionate, professional mental health services across the state. With five convenient office locations in Saint Johns, Alma, Midland, Howell, and Jackson, as well as virtual therapy options, we ensure that comprehensive mental health support is accessible to everyone. Our team of licensed therapists and psychiatric nurse practitioners is committed to offering personalized care for individuals, couples, and families. www.michiganpsychologicalcare.com
Contact Information
Lara Hakamaki
Director of Corporate Development
lara.hakamaki@ccmcpsych.com
(989) 292-3572
SOURCE: Michigan Psychological Care
View the original press release on newswire.com.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…
